Cardiotoxicity & Drug Discovery
Between 1990 and 2006 one third of all safety-related drug withdrawals were due to cardiotoxicity, and cardiac liability continues to be a major hurdle in drug development. There are ongoing efforts to develop higher throughput and more predictive assays that can be used earlier in the drug discovery/development pipeline to minimize both cost and risk. In Vitro Technologies provides a complete drug discovery and compound screening platform using the label-free, real-time cell analysis technologies from Agilent and ACEA Biosciences.
- xCELLigence SP & MP RTCA
- xCELLigence Cardio & CardioECR RTCA
- TocriScreen compound libraries
- Seahorse XF analyzer
Learn more about our range by clicking on the buttons below
Our Cardiotoxicity & Drug Discovery Brands
